查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年细胞遗传学市场预测：按产品、技术、用途、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1372035

2030 年细胞遗传学市场预测：按产品、技术、用途、最终用户和地区进行的全球分析

Cytogenetics Market Forecasts to 2030 - Global Analysis By Product, Technique, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球细胞遗传学市场规模为 27 亿美元，预计在预测期内年复合成长率为 11.8%，到 2030 年将达到 61 亿美元。

对染色体、基因及其在生物体结构中的结构和数值变异的研究属于细胞遗传学的广泛范畴，其中包括广泛的方法、设备和服务。细胞遗传学是一个重要的领域，有助于发现遗传异常、检测遗传疾病以及了解癌症等疾病的遗传背景。其应用领域为临床诊断、研究和个人化医疗。

根据世界卫生组织统计，2018年约有1,810万人新诊断出癌症，960万人死于癌症。

对细胞遗传学的高需求

细胞遗传学需求增加的原因有很多。首先，它对于了解癌症、出生缺陷和遗传疾病至关重要。此外，随着精准医疗的普及，基因诊断和个体化治疗计画变得越来越重要。此外，由于人们对遗传对健康和疾病的影响以及高龄化的认识不断加深，临床、研究和诊断用途对细胞遗传学检测的需求不断增加。因此，扩大人类基因组和疾病遗传学研究的需求不断增加。

高成本

细胞遗传学检测需要使用专门的工具、消耗品和训练有素的人员，所有这些都是昂贵的。患者通常需要申请这些费用，并且接受基因诊断和咨询的能力受到限制。它也可能给医院和研究机构造成财务困难。新细胞遗传学技术的创建和使用也受到高成本的阻碍。因此，这些方面都阻碍了市场的成长。

癌症治疗的新创新

随着癌症发生率的增加，许多分子细胞遗传学技术经常用于癌症诊断。此外，随着我们对染色体层面上癌症的了解不断加深，在癌症研究成长的推动下，细胞遗传学收益也不断扩大。例如，FISH 和 CGH 技术的使用促进了该市场的开拓，这些技术提供了与癌症相关的遗传标记的重要资讯。 FISH、染色体影像分析、流式分选和基因组原位杂交 (GISH) 是用于创建合成植物染色体的方法，并已用于创建遗传、物理、分子和比较图谱。此外，分子细胞遗传学在作物改良中的应用领域和优势的扩大正在支持市场的成长。

不利的报酬

不利的薪酬做法对细胞遗传学产业有害。由于付款不一致或不足，医疗保健提供者不太可能进行细胞遗传学检测和治疗，从而限制了患者的访问。此外，这也透过减少需求和降低研发的经济诱因来影响市场。此外，关于获得尖端细胞遗传学检测的衝突可能会阻止患者接受癌症和遗传性疾病等疾病的重要基因诊断。这是市场拓展的一大障碍。

COVID-19 的影响

细胞遗传学市场受到了 COVID-19大流行的负面影响。封锁和资源重新分配扰乱了实验室业务，导致基因检测延迟和患者准入问题。此外，经济不确定性限制了研究和测试项目的资金，供应链中断阻碍了获得所需的测试用品。此外，学术和临床研究活动也受到阻碍，导致临床和科学挫折。因此，这些要素极大地阻碍了市场的成长。

预计核型测试领域在预测期内将是最大的。

据估计，核型分析部分占最大份额。它通常从血液或组织样本中可视化并检查一个人的整个染色体。此外，核型分析有助于检测染色体结构和数值异常，有助于癌症、遗传性疾病和产前检测的诊断。此外，虽然更先进的技术（例如光谱核型分析和萤光原位杂交（FISH））提供了更高的解析度，但传统的核型分析程序（包括染色体染色和显微镜检查）将会出现。因此，核型分析因其对染色体异常和遗传疾病的宝贵见解而仍然是临床和研究细胞遗传学的基石。

个人化医疗领域预计在预测期内年复合成长率最高

由于根据患者个人化医疗调整医疗照护的领域迅速扩大，预计个人化医疗领域在预测期内将出现最高的年复合成长率。细胞遗传学程序，例如染色体分析和分子测试，使临床医生能够发现影响药物治疗反应、疾病易感性和整体健康的遗传差异。此外，该方法可以更准确地诊断和治疗选择，改善治疗结果并减少不良反应。此外，随着基因组学和细胞遗传学技术的进步，个人化医疗在罕见疾病、药物基因组学和癌症的鉴定中发挥关键作用，根据患者的基因图谱提供个体化的标靶治疗方案，从而彻底改变医疗保健。因此，有利于扩大市场规模。

比最大的地区

由于世界各国政府和学术机构透过资助和配合措施积极鼓励基因研究和诊断，亚太地区在估计期间获得了最大的市场占有率。例如，印度的「印度基因组计画」正试图创建印度基因组的综合图谱。此外，中国和日本等国家正在启动基因组学配合措施，以推进基因诊断和个人化医疗。此外，亚太地区正在成为基因研究、创新和临床应用的焦点，这些计画得到了大量多样化人口的支持。

复合年复合成长率最高的地区：

由于着名的研究机构、生物技术公司和医疗设施位于该地区，支持细胞遗传学的创新和研究，预计北美在预测期内将出现有益的增长。此外，强大的医疗保健系统和积极的政府政策促进了细胞遗传学检测融入临床实践，促进个人化医疗和精准医疗。此外，由于北美在细胞遗传学方面的领先地位和强大的法规环境，该地区处于基因诊断和研究的前沿，推动了市场的成长和进步。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球细胞遗传学市场：副产品

  • 消耗品
    • 检测套组、培养基和试剂
    • 探测
    • 亲和试剂和染色剂
    • 其他消耗品
  • 乐器
  • 软体和服务
  • 其他产品

第6章全球细胞遗传学市场：依技术分类

  • 比较基因组杂交
  • 萤光原位杂交
  • 核型分析
  • 免疫组织化学
  • 其他技术

第7章全球细胞遗传学市场：依应用分类

  • 遗传疾病
  • 癌症
  • 个人化医疗
  • 其他用途

第8章全球细胞遗传学市场：依最终用户分类

  • 临床研究室
  • 製药和生物技术公司
  • 学术研究
  • 其他最终用户

第9章全球细胞遗传学市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Thermo Fisher Scientific, Inc.
  • Sysmex Corporation
  • PerkinElmer, Inc.
  • OPKO Health, Inc.
  • Irvine Scientific
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Applied Spectrial Imaging, Inc.
  • Empire Genomics, LLC
Product Code: SMRC24091

According to Stratistics MRC, the Global Cytogenetics Market is accounted for $2.7 billion in 2023 and is expected to reach $6.1 billion by 2030 growing at a CAGR of 11.8% during the forecast period. The study of chromosomes, genes, and their structural and numerical variations within an organism's genetic makeup falls under the broad category of cytogenetics, which includes a wide range of methods, instruments, and services. It helps in locating genetic anomalies, detecting genetic disorders, and comprehending the genetic underpinnings of diseases like cancer, this field is crucial. Its applications are in clinical diagnostics, research, and personalized medicine.

According to WHO, in the year 2018 around 18.1 million new cases were diagnosed and 9.6 million individuals died out of cancer.

Market Dynamics:

Driver:

High demand for cytogenetics

Numerous reasons have contributed to the rise in cytogenetic demand. First of all, it is essential to comprehending cancer, birth deformities, and hereditary diseases. Moreover, genetic diagnosis and individualized treatment plans are becoming more and more important as precision medicine becomes more and more popular, cytogenetic testing is now more widely available, precise, and economical thanks to technological improvements. Furthermore, the demand for cytogenetics in clinical, research, and diagnostic applications keeps rising as a result of expanding understanding of the genetic contributions to health and illness as well as an aging population. Therefore, the expansion of research into the human genome and the genetics of diseases have increased demand.

Restraint:

High cost

Cytogenetic testing necessitates the use of specialized tools, consumables, and trained workers, all of which can be expensive. Patients are frequently charged for these costs, which restricts their ability to get genetic diagnostics and counseling. They can present financial difficulties for hospitals and research facilities. The creation and use of new cytogenetic technologies are also hampered by high costs. Hence, these aspects hinder the market growth.

Opportunity:

New innovations in cancer treatment

Numerous molecular cytogenetics techniques are being employed more frequently for cancer diagnosis as the incidence of the disease rises. In addition, as more is understood about cancer at the chromosomal level, this is causing the cytogenetics revenue to expand, which is being fueled by the growth of cancer research. For instance, the development of the market is facilitated by the use of FISH and CGH procedures, which offer vital information on cancer-related genetic markers. FISH, chromosomal image analysis, flow sorting, and genomic in-situ hybridization (GISH), methods used for the creation of synthetic plant chromosomes, are employed in the creation of genetic, physical, molecular, and comparative maps. Moreover, the rising application field and advantages of molecular cytogenetics in crop improvement are therefore assisting the market's growth.

Threat:

Unfavourable compensation

Unfavourable reimbursement practices have been detrimental to the cytogenetics industry. Healthcare providers are less likely to give cytogenetic testing and treatments as a result of inconsistent or insufficient payment, which restricts patient access. Moreover, in turn, this has an impact on the market by decreasing demand and the financial incentives for R&D. Additionally, it may result in disagreements over access to cutting-edge cytogenetic testing, preventing patients from receiving vital genetic diagnostics for diseases like cancer and genetic disorders. Therefore, it is significantly hindering market expansion.

COVID-19 Impact

The cytogenetics market was negatively impacted by the COVID-19 pandemic. Due to lockdowns and resource redistribution, it interfered with laboratory operations, causing delays in genetic testing and problems with patient access. Furthermore, economic uncertainty limited funding for research and testing projects, while supply chain interruptions hindered the accessibility of necessary testing supplies. Moreover, academic and clinical research operations were impeded, which resulted in clinical and scientific setbacks. Therefore, these factors significantly hampered the market growth.

The karyotyping segment is expected to be the largest during the forecast period

The karyotyping segment is estimated to hold the largest share. It entails the visualization and examination of a person's whole chromosomal set, usually from a blood or tissue sample. Additionally, karyotyping aids in the detection of chromosomal structure and numerical anomalies, which aid in the diagnosis of cancer, genetic diseases, and prenatal testing. Moreover, more sophisticated techniques like spectral karyotyping and fluorescent in situ hybridization (FISH) offer higher resolution, traditional karyotyping procedures include staining and microscopic inspection of chromosomes. Therefore, with the invaluable insights into chromosomal abnormalities and genetic illnesses, karyotyping continues to be a cornerstone in clinical and research cytogenetics.

The personalized medicine segment is expected to have the highest CAGR during the forecast period

The personalized medicine segment is anticipated to have highest CAGR during the forecast period, due to a quickly expanding area that adapts medical care to a patient's genetic profile. Clinicians can find genetic differences that affect a person's response to medication, susceptibility to diseases, and general health by utilizing cytogenetic procedures such as chromosomal analysis and molecular testing. Additionally, this method allows for more exact diagnostic and treatment choices, improving therapeutic results and reducing negative effects. Moreover, with improvements in genomics and cytogenetic technology, personalized medicine is playing a crucial role in the identification of uncommon diseases, pharmacogenomics, and cancers, revolutionizing healthcare by offering patients personalized and targeted treatment plans based on their genetic profiles. Thus, helps in expanding the market size.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to a number of initiatives, through funding and cooperative initiatives, governments and academic institutions from all around the region are actively encouraging genetic research and diagnostics. For instance, the "Genome India Project" in India attempts to produce an exhaustive map of the Indian genome. Moreover, nations like China and Japan have launched genomics efforts to advance genetic diagnoses and tailored medicine. Furthermore, the Asia-Pacific area is becoming a focus point for genetic studies, innovations, and clinical applications due to these programs, which are supported by a sizable and diversified population.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to renowned research institutions, biotech firms, and medical facilities are located in the area, which supports cytogenetics innovation and study. Additionally, robust healthcare systems and proactive government policies have made it easier to incorporate cytogenetic testing into clinical practice, promoting personalized and precision medicine. Furthermore, the region is at the forefront of genetic diagnostics and research due to North America's leadership in cytogenetics and a strong regulatory environment, which promotes market growth and advancements.

Key players in the market:

Some of the key players in the Cytogenetics Market include: Thermo Fisher Scientific Inc., Sysmex Corporation, PerkinElmer, Inc., OPKO Health, Inc., Irvine Scientific, Abbott Laboratories, Agilent Technologies, Inc., Applied Spectrial Imaging, Inc. and Empire Genomics, LLC.

Key Developments:

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

In August 2023, Thermo Fisher Scientific Inc. the world leader in serving science, announced that it has completed the acquisition of CorEvitas, LLC ("CorEvitas"), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity ("Audax).

In August 2023, Thermo Fisher Scientific, the world leader in serving science, announced the commercial launch of the EXENT® Solution, after receiving IVDR certification*. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma.

Products Covered:

  • Consumable
  • Instrument
  • Software & Service
  • Other Products

Techniques Covered:

  • Comparitive Genome Hybridization
  • Fluorescence In Situ Hybridization
  • Karyotyping
  • Immunohistochemistry
  • Other Techniques

Applications Covered:

  • Genetic Disorder
  • Cancer
  • Personalized Medicine
  • Other Applications

End Users Covered:

  • Clinical and Research Laboratory
  • Pharmaceutical and Biotechnology Company
  • Academic Research Institute
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cytogenetics Market, By Product

  • 5.1 Introduction
  • 5.2 Consumable
    • 5.2.1 Testing Kits, Media, and Reagents
    • 5.2.2 Probes
    • 5.2.3 Affinity Reagents and Stains
    • 5.2.4 Other Consumables
  • 5.3 Instrument
  • 5.4 Software & Service
  • 5.5 Other Products

6 Global Cytogenetics Market, By Technique

  • 6.1 Introduction
  • 6.2 Comparitive Genome Hybridization
  • 6.3 Fluorescence In Situ Hybridization
  • 6.4 Karyotyping
  • 6.5 Immunohistochemistry
  • 6.6 Other Techniques

7 Global Cytogenetics Market, By Application

  • 7.1 Introduction
  • 7.2 Genetic Disorder
  • 7.3 Cancer
  • 7.4 Personalized Medicine
  • 7.5 Other Applications

8 Global Cytogenetics Market, By End User

  • 8.1 Introduction
  • 8.2 Clinical and Research Laboratory
  • 8.3 Pharmaceutical and Biotechnology Company
  • 8.4 Academic Research Institute
  • 8.5 Other End Users

9 Global Cytogenetics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Thermo Fisher Scientific, Inc.
  • 11.2 Sysmex Corporation
  • 11.3 PerkinElmer, Inc.
  • 11.4 OPKO Health, Inc.
  • 11.5 Irvine Scientific
  • 11.6 Abbott Laboratories
  • 11.7 Agilent Technologies, Inc.
  • 11.8 Applied Spectrial Imaging, Inc.
  • 11.9 Empire Genomics, LLC

List of Tables

  • Table 1 Global Cytogenetics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 4 Global Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 5 Global Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 6 Global Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 7 Global Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 8 Global Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 9 Global Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 10 Global Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 11 Global Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 12 Global Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 13 Global Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 14 Global Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 15 Global Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 16 Global Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 17 Global Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 18 Global Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 19 Global Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 20 Global Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 21 Global Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 22 Global Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 24 Global Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 25 Global Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 26 Global Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 27 North America Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 29 North America Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 30 North America Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 31 North America Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 32 North America Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 33 North America Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 34 North America Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 35 North America Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 36 North America Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 37 North America Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 38 North America Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 39 North America Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 40 North America Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 41 North America Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 42 North America Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 43 North America Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 44 North America Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 45 North America Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 46 North America Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 47 North America Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 48 North America Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 North America Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 50 North America Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 51 North America Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 52 North America Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 53 Europe Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 55 Europe Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 56 Europe Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 57 Europe Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 58 Europe Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 59 Europe Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 60 Europe Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 61 Europe Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 62 Europe Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 63 Europe Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 64 Europe Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 65 Europe Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 66 Europe Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 67 Europe Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 68 Europe Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 69 Europe Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 70 Europe Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 71 Europe Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 72 Europe Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 73 Europe Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 74 Europe Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Europe Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 76 Europe Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 77 Europe Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 78 Europe Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 79 Asia Pacific Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 81 Asia Pacific Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 82 Asia Pacific Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 83 Asia Pacific Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 84 Asia Pacific Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 85 Asia Pacific Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 86 Asia Pacific Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 87 Asia Pacific Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 88 Asia Pacific Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 89 Asia Pacific Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 90 Asia Pacific Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 91 Asia Pacific Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 92 Asia Pacific Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 93 Asia Pacific Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 94 Asia Pacific Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 95 Asia Pacific Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 96 Asia Pacific Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 97 Asia Pacific Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 98 Asia Pacific Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 99 Asia Pacific Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 100 Asia Pacific Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 101 Asia Pacific Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 102 Asia Pacific Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 103 Asia Pacific Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 104 Asia Pacific Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 105 South America Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 107 South America Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 108 South America Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 109 South America Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 110 South America Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 111 South America Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 112 South America Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 113 South America Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 114 South America Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 115 South America Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 116 South America Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 117 South America Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 118 South America Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 119 South America Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 120 South America Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 121 South America Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 122 South America Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 123 South America Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 124 South America Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 125 South America Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 126 South America Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 127 South America Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 128 South America Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 129 South America Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 130 South America Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 131 Middle East & Africa Cytogenetics Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Cytogenetics Market Outlook, By Product (2021-2030) ($MN)
  • Table 133 Middle East & Africa Cytogenetics Market Outlook, By Consumable (2021-2030) ($MN)
  • Table 134 Middle East & Africa Cytogenetics Market Outlook, By Testing Kits, Media, and Reagents (2021-2030) ($MN)
  • Table 135 Middle East & Africa Cytogenetics Market Outlook, By Probes (2021-2030) ($MN)
  • Table 136 Middle East & Africa Cytogenetics Market Outlook, By Affinity Reagents and Stains (2021-2030) ($MN)
  • Table 137 Middle East & Africa Cytogenetics Market Outlook, By Other Consumables (2021-2030) ($MN)
  • Table 138 Middle East & Africa Cytogenetics Market Outlook, By Instrument (2021-2030) ($MN)
  • Table 139 Middle East & Africa Cytogenetics Market Outlook, By Software & Service (2021-2030) ($MN)
  • Table 140 Middle East & Africa Cytogenetics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 141 Middle East & Africa Cytogenetics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 142 Middle East & Africa Cytogenetics Market Outlook, By Comparitive Genome Hybridization (2021-2030) ($MN)
  • Table 143 Middle East & Africa Cytogenetics Market Outlook, By Fluorescence In Situ Hybridization (2021-2030) ($MN)
  • Table 144 Middle East & Africa Cytogenetics Market Outlook, By Karyotyping (2021-2030) ($MN)
  • Table 145 Middle East & Africa Cytogenetics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 146 Middle East & Africa Cytogenetics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 147 Middle East & Africa Cytogenetics Market Outlook, By Application (2021-2030) ($MN)
  • Table 148 Middle East & Africa Cytogenetics Market Outlook, By Genetic Disorder (2021-2030) ($MN)
  • Table 149 Middle East & Africa Cytogenetics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 150 Middle East & Africa Cytogenetics Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 151 Middle East & Africa Cytogenetics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 152 Middle East & Africa Cytogenetics Market Outlook, By End User (2021-2030) ($MN)
  • Table 153 Middle East & Africa Cytogenetics Market Outlook, By Clinical and Research Laboratory (2021-2030) ($MN)
  • Table 154 Middle East & Africa Cytogenetics Market Outlook, By Pharmaceutical and Biotechnology Company (2021-2030) ($MN)
  • Table 155 Middle East & Africa Cytogenetics Market Outlook, By Academic Research Institute (2021-2030) ($MN)
  • Table 156 Middle East & Africa Cytogenetics Market Outlook, By Other End Users (2021-2030) ($MN)